TSX symbol: SBS
CALGARY, March 13 /CNW/ - SemBioSys Genetics Inc. (TSX: SBS), a
biotechnology company developing a portfolio of therapeutic proteins for
metabolic and cardiovascular diseases, today announced that it has been
granted European patent EP0986309(B1) entitled "Uses of Oil Bodies". The
patent has been issued to SemBioSys, which has exclusively licensed commercial
rights associated with the patent to Botaneco Specialty Ingredients Inc.
(Botaneco), its wholly owned subsidiary. The claims of European Patent
EP0986309(B1) are broadly directed to the production of emulsions comprising
oleosomes extracted from any living cell, including plants such as safflower,
and the use of these emulsions in a wide range of commercial applications
including food ingredient, personal care and over-the-counter as well as
"This patent demonstrates our commitment to diligently protect our
proprietary oleosome technology. It provides broad coverage for the production
of personal care, topical OTC and pharmaceutical, food and other products
based on emulsions comprised of oleosomes in the European market," said Andrew
Baum, President and CEO of SemBioSys. "The issuance of this patent further
validates our leadership in the use of oilbodies in personal care and other
topical applications. We plan to launch Hydresia(TM), Botaneco's first
oleosome based ingredient, in Europe this spring after a successful launch in
the U.S. and Canada last year."
Counterparts to the European patent EP0986309(B1) have issued in many
jurisdictions worldwide including the United States, Canada, Australia, Japan,
China, India and Mexico.
In September of 2007, Botaneco commissioned its new 10,000 square foot,
state-of-the-art commercial manufacturing facility for the production of its
all natural oleosome base emulsion for the personal care and cosmetic markets.
Botaneco recently announced that its first international brand customer,
Burt's Bees, launched three personal care products in the U.S. using
Botaneco's Hydresia(TM) ingredient.
About SemBioSys Genetics Inc. (www.sembiosys.com)
Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company
developing protein-based pharmaceuticals for metabolic and cardiovascular
diseases. The Company's lead pharmaceutical candidates, produced in the plant
host safflower, are recombinant human insulin to serve the rapidly expanding
global diabetes market and Apo AI, a next generation cardiovascular drug. In
addition to its pharmaceutical products, SemBioSys is developing a series of
non-pharmaceutical products addressing human topical, nutritional oils and
agricultural biotechnology markets.
About Botaneco (www.botaneco.ca)
From development through delivery, Botaneco manufactures and markets a
branded line of ingredients that harness the naturally occurring benefits of
protein protected seed oils. Botaneco provides performance, innovation and
choice in creating natural, renewable and versatile delivery systems and
ingredients used in the development of cosmetics, personal care and
prescription topical/dermatology products beneficial to humans and the
environment. Botaneco is a wholly-owned subsidiary of SemBioSys Genetics Inc.
About Hydresia(TM) (www.hydresia.com)
Hydresia(TM) is a base emulsion naturally derived from safflower seed
oilbodies, or oleosomes, which can replace such traditional emulsifiers as
petrolatum and animal byproducts in health and beauty products. Oleosomes
serve as natural storehouses for the emollient oils, antioxidants and natural
moisture barriers that help keep skin soft, supple and young looking.
SemBioSys has developed a gentle and natural proprietary process to isolate
oleosomes from the seed fully intact to provide lasting protection to the
This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable Canadian securities laws.
Forward-looking statements reflect the Company's current expectation and
assumptions, and are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those anticipated. These
forward-looking statements involve risks and uncertainties including, but not
limited to, changing market conditions, the successful and timely completion
of clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from
time-to-time in the Company's ongoing filings with the Canadian securities
regulatory authorities which filings can be found at www.sedar.com. Given
these risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. The Company undertakes no
obligation to publicly update or revise any forward-looking statements either
as a result of new information, future events or otherwise, except as required
by applicable Canadian securities laws.
For further information:
For further information: SemBioSys Genetics Inc., Mr. Andrew Baum,
President and Chief Executive Officer, Phone: (403) 717-8767, Fax: (403)
250-3886, E-mail: firstname.lastname@example.org, Internet: www.sembiosys.com; Investor
Relations, Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext.
238), Fax: (416) 815-0080, E-mail: email@example.com